Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ispectamab debotansine
- Development stage
- Discontinued
- Lead developer
- Bristol Myers Squibb
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ispectamab debotansine (CC-99712, BMS-986352) is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA), developed through a collaboration between Sutro Biopharma and Celgene (now Bristol Myers Squibb). It was engineered using Sutro's proprietary XpressCF cell-free protein synthesis platform, which allows for site-specific conjugation. The ADC consists of a humanized IgG1 monoclonal antibody conjugated to a maytansinoid payload, debotansine (N2'-deacetylmaytansine), via a non-cleavable dibenzocyclooctyne (DBCO) linker. Upon binding to BCMA on the surface of malignant plasma cells, the conjugate is internalized, and the payload inhibits tubulin polymerization, leading to cell cycle arrest and apoptosis. It was primarily investigated for the treatment of relapsed and refractory multiple myeloma. Development was discontinued by Bristol Myers Squibb in 2023.
- Other names
- ispectamab debotansine
02
Targets
TUBB (Tubulin (alpha and beta subunits))BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on ispectamab debotansine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ispectamab debotansine.